X0306 4 2014-07-22 0 0001472343 Roka BioScience, Inc. ROKA 0001270521 KOLLURI KRISHNA KITTU 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 0 0 1 0 Common Stock 2014-07-22 4 C 0 1119565 A 1124299 I See Note 1 Common Stock 2014-07-22 4 C 0 365056 A 1489355 I See Note 1 Common Stock 2014-07-22 4 C 0 801741 A 2291096 I See Note 1 Common Stock 2014-07-22 4 C 0 542381 A 2833477 I See Note 1 Common Stock 2014-07-22 4 P 0 383333 12 A 3216810 I See Note 1 Series B Preferred Stock 2014-07-22 4 C 0 12360000 D 2009-09-10 Common Stock 1119565 0 I See Note 1 Series C Preferred Stock 2014-07-22 4 C 0 4030224 D 2011-04-29 Common Stock 365056 0 I See Note 1 Series D Preferred Stock 2014-07-22 4 C 0 8555784 D 2011-12-19 Common Stock 801741 0 I See Note 1 Series E Preferred Stock 2014-07-22 4 C 0 5987892 D 2013-06-13 Common Stock 542381 0 I See Note 1 The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest. The shares of Series B Preferred Stock have no expiration date and automatically converted upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series B Preferred Stock to 0.0906 shares of common stock, for no additional consideration. Such conversion is reflected in the amount of common stock underlying the security. The shares of Series C Preferred Stock have no expiration date and automatically converted upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.0906 shares of common stock, for no additional consideration. Such conversion is reflected in the amount of common stock underlying the security. The shares of Series D Preferred Stock have no expiration date and automatically converted upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.0937 shares of common stock, for no additional consideration. Such conversion is reflected in the amount of common stock underlying the security. The shares of Series E Preferred Stock have no expiration date and automatically converted upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.0906 shares of common stock, for no additional consideration. Such conversion is reflected in the amount of common stock underlying the security. /s/ Sasha Keough, attorney-in-fact 2014-07-22